Recent genetic studies identified CD6 variants as susceptibility or disease-modifying markers for autoimmune disorders (e.g., multiple sclerosis, inflammatory bowel disease, Behçet’s disease, psoriasis, and rheumatoid arthritis), prompting its evaluation as a potential therapeutic target (2–4). This evidence concerns the gene CD6 and psoriasis.